Cancer Treatment Reviews

Article	Citations
Editorial Board	262
Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis	198
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming	177
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer	161
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors	141
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review	124
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty	116
The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology	95
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis	94
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer	93
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	93
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)	81
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in	80
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials	77
Proton therapy in breast cancer: bridging medical and radiation oncology	75
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives	75
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches	68
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis	68
Editorial Board	61
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma	59
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era	58
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?	57
If it’s a target, it’s a pan-cancer target: Tissue is not the issue	55
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment	55
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.	54

Emerging antibody-based therapies for the treatment of acute myeloid leukemia	54
Optimizing care in early phase cancer trials: The role of palliative care	53
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications	53
Revisiting patient preference in resectable and irradiable stage III NSCLC in the immunotherapy era	53
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment	51
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC	51
De-escalation strategies with targeted therapies in non-small cell lung cancer	51
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials	51
Uncertainties and controversies in axillary management of patients with breast cancer	50
Editorial Board	50
Editorial Board	50
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes	49
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation	48
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?	48
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck	47
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?	47
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation	47
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy	47
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis	46
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations	46
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier	43
Extracellular vesicles and the “six Rs” in radiotherapy	43
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review	41
Corrigendum to “The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management”. [Cancer Treat. Rev. 139 (2025) 102998]	41
Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG)	41
Editorial Board	41
The immunogram of inflammatory breast cancer	40
Overview of BH3 mimetics in ovarian cancer	39
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis	38
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada	38
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design	38
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features	38
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers	36
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside	36
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma	35
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma	34
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)	33
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review	33
Long-term surveillance recommendations for young adult cancer survivors	33
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review	32
Expanding the therapeutic Frontier: Liver transplantation for unresectable colorectal liver metastases	32
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies	32
Editorial Board	32
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer	31
Assessing lung function in women treated for breast cancer with radiotherapy. A comprehensive systematic review and meta-analysis	31
Systematic review of the CUP trials characteristics and perspectives for next-generation studies	31
Immunocytokines in cancer treatment: A systematic review	31
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer	30
Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review	30
Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials	30

Malignant ascites: Current therapy options and treatment prospects	29
Editorial Board	29
Bone complications of cancer treatment	29
Editorial Board	29
Agnostic drug development revisited	29
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life	29
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review	29
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review	28
Corrigendum to “T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis”. [Cancer Treat Rev. 139 (2025) 102991. doi: 10.1016/j.ctrv.2025.102991]	28
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review	28
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?	27
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review	27
Genomic distinctions in adolescent and young adult cancer: A comprehensive review	27
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers	27
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges	26
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review	26
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes	26
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis	26
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification	26
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project	25
Local control strategies for management of NSCLC with oligoprogressive disease	25
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives	25
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review	25
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie	25
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?	25
Evolving immunotherapeutic solutions for triple-negative breast carcinoma	24
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis	24
Strategies for improving detection of circulating tumor DNA using next generation sequencing	24
Management of infections in the outpatient care of patients with cancer	24
Engineering strategies to optimise adoptive cell therapy in ovarian cancer	23
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis	23
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]	23
Review: Targeting EZH2 in neuroblastoma	23
Pharmacotherapy for leptomeningeal disease in breast cancer	23
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies	23
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer	23
Editorial Board	23
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis	22
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives	22
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies	22
Editorial Board	22
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review	22
Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis	22
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment	22
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications	21
Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges	21
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression	21
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review	21
Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non–small cell lung cancer	21
Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy	21
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases	20
An umbrella review of systematic reviews on the diagnostic and prognostic utility of circulating tumor DNA and MicroRNA in colorectal cancer	20
Editorial Board	20
Editorial Board	20
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672]	20
Editorial Board	20
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments	20
Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas	19
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)	19
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy	19
Challenges to genetic testing for germline mutations associated with breast cancer among African Americans	19
Considerations regarding a network meta-analysis of targeted therapies for BRAF-mutant unresectable or metastatic melanoma	19
From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia	19
Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma	19
Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer	18
Multimodality treatment of primary cardiac angiosarcoma: A systematic literature review	18
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines	18
A systematic review of eHealth technologies for breast cancer supportive care	18
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action	18
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?	18
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group	18
Erratum to “Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review”. [Cancer Treat. Rev. 140 (2025) 103024]	18
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?	17
Advances in treatment strategies for low-grade serous ovarian cancer	17
T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis	17
Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives	17
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis	17
Germline TP53 pathogenic variants and breast cancer: A narrative review	17
Clinical course and treatment outcomes in solid-basaloid adenoid cystic carcinoma of the breast: A systematic review and case report	17
Corrigendum to “PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives” [Cancer Treat. Rev. 131 (2024) 102850]	16

CAR-T cell therapy for breast cancer: Current status and future perspective	16
Harnessing epigenetics: Genome-wide DNA methylation assay for colorectal cancer therapy	16
First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis	16
Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist	16
Clearer Horizons: The latest advances in clear cell ovarian cancer treatment	16
Local administration of immunotherapy for patients with skin cancer: A systematic review	16
BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives	16
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer	16
Current controversies in the use of Oncotype DX in early breast cancer	15
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice	15
Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis	15
Editorial Board	15
Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians	15
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review	15
Exercise in patients with metastatic prostate cancer: A comprehensive review	15
Acquired resistance mechanisms to osimertinib: The constant battle	14
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing	14
Editorial Board	14
Editorial Board	14
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management	14
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck	14
Editorial Board	14
Biomarker-guided immunotherapy in gastric cancer: current insights and future perspectives	14
Neoadjuvant therapy and translational biomarkers for metastatic risk in early breast cancer	13
Chimeric antigen receptor NK cells for breast cancer immunotherapy	13
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?	13
Editorial Board	13
Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integration	13
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer	13
Editorial Board	13
Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group	13
Beyond HER2: Targeting the ErbB receptor family in breast cancer	13
Enhancing radiotherapy techniques for Triple-Negative breast cancer treatment	13
Antibody based therapies in Hodgkin lymphoma	13
Rethinking endpoints for the watch-and-wait strategy in rectal cancer	12
Insights into RAS-driven melanoma and its therapeutic implications	12
Molecular aspects of brain metastases in breast cancer	12
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy	12
European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer	12
Primary tumor and metastasis-directed treatment for oligometastatic prostate cancer: An umbrella review of meta-analyses	12
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer	12
Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives	12
Editorial Board	12
Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into ac	12
The current clinical landscape of personalized cancer vaccines	12
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer	12
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development	12
Bone metastases in NSCLC: Modern paradigms in management and supportive care	12
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma	11
Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies	11
Editorial Board	11
Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation	11
Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials	11
Immunotherapy-based combinations in metastatic NSCLC	11
Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment	11
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors	11
Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review	11
Editorial Board	11
Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review	11
Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis	10
Long road towards effective HER3 targeting in breast cancer	10
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges	10
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis	10
Editorial Board	10
Evolving therapeutics and ensuing cardiotoxicities in triple-negative breast cancer	10
Corrigendum to “Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis” [Cancer Treat. Rev. 125 (2024) 102704]	10
Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck	10
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma	10
Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities	10
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists	10
Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody–Drug conjugates	10
Phase III placebo-controlled oncology trials in the last decade: evolution, methodological foundations, and clinical impact	10
Physical activity reduces all-cause mortality in patients with cancer: a systematic review and meta-analysis of randomized controlled trials	10
Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials	10
Pathologic complete response in patients with localized soft tissue sarcoma treated with neoadjuvant therapy and its correlation with clinical outcomes: A systematic review	10
Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials	10
First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States	10
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer	9
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer	9
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer	9
Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review	9
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials	9
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev.	9
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome	9
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective	9
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers	9
Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy	9
Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma	9
Integrating antibody-drug conjugates into the management of early breast cancer	9
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies	8
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives	8
NTRK gene fusion testing and management in lung cancer	8
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force	8
Compliance to chemoradiation in squamous cell carcinoma of the anus	8
The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment	8